203520-03-0

Basic information

• Product Name: 4-(PIPERIDINE-4-CARBONYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-(PIPERIDINE-4-CARBONYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;BUTTPARK 93\50-43;1-PIPERAZINECARBOXYLIC ACID, 4-(4-PIPERIDINYLCARBONYL)-, 1,1-DIMETHYLETHYL ESTER;tert-butyl 4-(piperidine-4-carbonyl)piperazine-1-carboxylate;Tert-Butyl 4-[(Piperidin-4-Yl)Carbonyl]Piperazine-1-Carboxylate;Tert-Butyl 4-[(Piperidin-4-Yl)Carbonyl]Piperazine-1-Carboxylate(WX180001)
• CAS NO: 203520-03-0
• Molecular Formula: C₁₅H₂₇N₃O₃
• Molecular Weight: 297.39
• Mol File: 203520-03-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(PIPERIDINE-4-CARBONYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PIPERIDINE-4-CARBONYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(203520-03-0)
• EPA Substance Registry System: 4-(PIPERIDINE-4-CARBONYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(203520-03-0)

Safety Data

• Hazardous Substances Data: 203520-03-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(PIPERIDINE-4-CARBONYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a chemical intermediate for the preparation of pyrrolopyrimidinylphenylbenzamides. These compounds act as BTK inhibitors, which are crucial in the development of drugs targeting various diseases, including autoimmune and inflammatory disorders, as well as certain types of cancer. The inhibition of BTK can help regulate immune cell activation and signaling pathways, making it a promising therapeutic approach for these conditions.

Upstream product

• 203520-02-9 1-(tert-butoxycarbonyl)-4-[1-benzyloxycarbonylpiperidin-4-ylcarbonyl]piperazine 
• 498-94-2 isonipecotic acid 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Relevant articles and documents

NOVEL HETEROCYCLIC COMPOUNDS

The invention provides novel heterocyclic compounds having thegeneral formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R4, m, n, and p are as described herein. Formula (I). Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES

The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

Heterocyclic compounds useful as oxido-squalene cyclase inhibitors

This invention concerns heterocyclic derivatives of formula (I) which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocycl

A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase

A novel series of 4-piperidinopyridines and 4-piperidinopyrimidines showed potent and selective inhibition of rat 2,3-oxidosqualene cyclase-lanosterol synthase (OSC) (e.g. 26 IC50 rat = 398 ± 25 nM, human = 112 ± 25 nM) and gave selective oral inhibition of rat cholesterol biosynthesis (26 ED80 = 1.2 ± 0.3 mg/kg, n = 5; HMGCoA reductase inhibitor simvastatin ED80 = 1.2 ± 0.3 mg/kg, n = 5). The piperidinopyrimidine OSC inhibitors have a significantly lower pKa than the corresponding pyridine or the previously reported quinuclidine OSC inhibitor series. This indicates that other novel OSC inhibitors may be found in analogues of this series across a broader pKa range (6.0-9.0). These series may yield novel hypocholesterolemic agents for the treatment of cardiovascular disease.

Substituted pyrimidine derivatives and their pharmaceutical use

PCT No. PCT/GB97/02029 Sec. 371 Date Feb. 12, 1999 Sec. 102(e) Date Feb. 12, 1999 PCT Filed Jul. 25, 1997 PCT Pub. No. WO98/06705 PCT Pub. Date Feb. 19, 1998This invention concerns heterocyclic derivatives which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.